Home > Insider Trading > Filing (0001213900-19-024996)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1484565	Soleno Therapeutics Inc	SLNO	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1398936	Vivo Ventures V Affiliates Fund, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No
1398937	Vivo Ventures Fund V, L.p.	C/O Vivo Capital Llc 192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No
1399028	Vivo Ventures V, Llc	192 Lytton Avenue Palo Alto CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-11-26	15,171	$1.55	3,670,731	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-11-27	2,898	$1.53	3,667,833	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The shares of common stock are held of record by Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. ("Vivo Fund V"). Vivo Ventures V, LLC is the sole general partner of Vivo Fund V, and may be deemed to beneficially own the shares of common stock owned by Vivo Fund V. Vivo Ventures V, LLC disclaims beneficial ownership of the shares of Issuer held by Vivo Fund V, except to the extent of its pecuniary interest therein. The voting members of Vivo Ventures V, LLC are Frank Kung, Albert Cha and Edgar Engleman, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.